Iron with folic acid supplemenation and birth weight in Ethiopia: Systemic review and meta-analysis

Abstract Background Previous studies on iron with folic acid supplementation and low birth weight indicated different findings. The aim of the current systemic review and meta-analysis was to examine the relationship between iron and folic acid supplementation and birth weight in Ethiopia. Main body The databases searched were PubMed, Google Scholar, Web of Science and Cochrane Library in January 2021. AZ, KTT and AAA carried out the data extraction and independently assessed the articles for inclusion in the review using risk-of-bias tool guided by PRISMA checklist. The combined Odds ratio with 95% confidence interval was calculated using random effect model. Twenty four observational studies involving 10,989 participants, 2423 newborns who were born LBW were included. The combined effect size (OR) for low birth weight comparing women who have Iron and Folic acid supplementation versus women who did not have iron and folic acid supplementation was 0.39 (95% CI 0.27–0.59, p < 0.00001, I2 = 91%). There was significant heterogeneity (Q = 264.16, I2 = 91%, p < 0.00001). No publication bias was observed (Egger’s test: p = 0.742, Begg’s test: p = 0.372). Overall 69.5% of women reported having iron and folic acid supplementation during current pregnancy. And the overall proportion of low birth weight was 22.1%. Conclusions Women who were supplied with iron and folic acid during pregnancy had a 67% decreased chance of delivering low birth weight new born in Ethiopia.

Download Full-text

Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis

Clinical & Investigative Medicine ◽

10.25011/cim.v39i4.27091 ◽

2016 ◽

Vol 39 (4) ◽

pp. 120 ◽

Cited By ~ 13

Author(s):

Xingrong Tan ◽

Shengbing Li ◽

Ying Chang ◽

Chao Fang ◽

Hua Liu ◽

...

Keyword(s):

Systematic Review ◽

Birth Weight ◽

Polycystic Ovary ◽

Meta Analysis ◽

Systemic Review ◽

Metformin Treatment ◽

Fetal Abnormality ◽

Significant Difference ◽

Fetal Birth Weight ◽

Continued Use

Purpose: Some previous studies have found that continued metformin use is beneficial in the management of polycystic ovary syndrome (PCOS) in pregnant women. A systemic review and meta-analysis were needed to more fully assess the effects of metformin on pregnant PCOS patients. Methods: The literature was fully searched using MEDLINE, EMBASE, SCOPUS, and COCHRANE for continued metformin use during pregnancy in women with PCOS. A systematic review and meta-analysis were performed to evaluate the comprehensive effects of continued metformin treatment on pregnancy-related outcomes in these women. Results: Eleven eligible studies out of 127 relevant publications were included in meta-analysis. The rates of early pregnancy loss and preterm delivery were found to be significantly decreased in metformin-treated PCOS women. A non-significant difference was found in fetal abnormality and fetal birth weight between the metformin-treated and the non-treated groups. The incidence of gestational diabetes mellitus (GDM) and hypertension/preeclampsia were not significantly different in the two groups, probably because of inconsistent results in the subgroup analysis. Conclusions: Our results showed that continued use during of metformin, during pregnancy in women with PCOS, had no effect on incidence of fetal abnormalities or fetal birth weight. The effects of metformin on GDM and hypertension/preeclampsia should be determined through high-quality randomized controlled trials.

Download Full-text